NYSE · Healthcare · Biotechnology · USA
Nuvation Bio Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Nuvation Bio is a global oncology company developing novel small molecules targeting validated cancer pathways. The company leverages expertise in medicinal chemistry and drug development to create therapies addressing limitations of existing treatments, with a commercial-stage product IBTROZI for ROS1-positive non-small cell lung cancer and clinical candidates including safusidenib for brain tumors.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Nuvation Bio Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.
17 more funds hold it; the full list is part of the paid plan.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on NUVB yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-20 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.